Please assess the completion status of the following clinical trial:

Trial Title: Post-Approval Clinical Study of the Talent Thoracic Stent Graft to Treat Thoracic Aortic Aneurysms (THRIVE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: appropriate anatomy for elective repair of the descending thoracic aortic aneurysm~* iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and or accessories~* non-aneurysmal aortic diameter in the range of 18-42mm; and~* non-aneurysmal aortic proximal and distal neck lengths equal to or greater than 20mm~* subject has a Descending Fusiform Thoracic Aneurysm = to or greater than 5cm in diameter OR is = to or greater than 2 times the diameter of the non-aneurysmal thoracic aorta and/or saccular aneurysms/penetrating ulcers~* Signed patient informed consent~Exclusion Criteria:~* Less than 18 yrs old~* pregnant~* unable to comply w/follow-up~* participating in other drug or device trials;~* Subject has a co-morbidity causing expected survival to be less than 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DeNovo (Type: EXPERIMENTAL): Prospectively enrolled subjects treated with the Talent Thoracic Stent Graft System following U.S. market approval of the device.
- Valor (Type: NO_INTERVENTION): Historical control arm, consisting of 195 subjects from the VALOR Test Group (PMA P070007) that were followed for 5 years per the VALOR protocol. The data from these subjects will be combined with the data from the subjects implanted after commercial release (DeNovo) to comprise the final analysis cohort for the THRIVE Study

Based on this trial design, predict the completion outcome and termination type (if applicable).